M&A Deal Summary

Nalpropion Pharmaceuticals Acquires OREXIGEN Therapeutics

On April 24, 2018, Nalpropion Pharmaceuticals acquired life science company OREXIGEN Therapeutics for 75M USD

Acquisition Highlights
  • This is Nalpropion Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Nalpropion Pharmaceuticals’ largest (disclosed) transaction.
  • This is Nalpropion Pharmaceuticals’ 1st transaction in the United States.
  • This is Nalpropion Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2018-04-24
Target OREXIGEN Therapeutics
Sector Life Science
Buyer(s) Nalpropion Pharmaceuticals
Deal Type Special Situations/Distressed
Deal Value 75M USD

Target

OREXIGEN Therapeutics

La Jolla, California, United States
Orexigen Therapeutics, Inc. is a bio-pharmaceutical company focuses on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Nalpropion Pharmaceuticals

San Diego, California, United States
Category Company
Founded 2018
Sector Life Science
DESCRIPTION

Nalpropion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of weight loss. Nalpropion Pharmaceuticals was formed in 2018 and is based in San Diego, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Special Situations/Distressed) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal